Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
7.54
+0.13 (1.75%)
Nov 4, 2024, 4:00 PM EST - Market closed
Adverum Biotechnologies Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ADVM stock have an average target of 28.17, with a low estimate of 12 and a high estimate of 40. The average target predicts an increase of 273.61% from the current stock price of 7.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 14, 2024.
Analyst Ratings
The average analyst rating for ADVM stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +430.50% | Aug 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +297.88% | Aug 13, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $15 → $12 | Hold | Maintains | $15 → $12 | +59.15% | Aug 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 → $40 | Strong Buy | Maintains | $4 → $40 | +430.50% | Jul 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $25 | Buy | Initiates | $25 | +231.56% | Jun 25, 2024 |
Financial Forecast
Revenue This Year
209.10K
from 3.60M
Decreased by -94.19%
Revenue Next Year
12.44M
from 209.10K
Increased by 5,848.83%
EPS This Year
-5.10
from -11.62
EPS Next Year
-4.83
from -5.10
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.1M | 63.0M | 63.0M | ||
| Avg | 209,100 | 12.4M | 20.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -70.1% | 30,029.1% | 406.5% | ||
| Avg | -94.2% | 5,848.8% | 66.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.32 | -2.77 | -2.46 | ||
| Avg | -5.10 | -4.83 | -4.49 | ||
| Low | -5.84 | -5.64 | -5.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.